Brokers Issue Forecasts for 10x Genomics Q3 Earnings

10x Genomics, Inc. (NASDAQ:TXG) – Equities research analysts at William Blair issued their Q3 2025 earnings per share (EPS) estimates for 10x Genomics in a research report issued to clients and investors on Thursday, February 13th. William Blair analyst M. Larew forecasts that the company will post earnings per share of ($0.33) for the quarter. The consensus estimate for 10x Genomics’ current full-year earnings is ($1.43) per share. William Blair also issued estimates for 10x Genomics’ Q4 2025 earnings at ($0.32) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.02) EPS and FY2026 earnings at ($1.02) EPS.

Other equities analysts also recently issued reports about the company. Canaccord Genuity Group decreased their price target on 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Leerink Partners downgraded 10x Genomics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $25.00 to $12.00 in a research note on Thursday, February 13th. Leerink Partnrs downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, February 1st. Finally, JPMorgan Chase & Co. cut their target price on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, 10x Genomics currently has an average rating of “Hold” and a consensus target price of $20.57.

10x Genomics Stock Performance

NASDAQ:TXG opened at $12.07 on Monday. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -7.89 and a beta of 1.85. 10x Genomics has a one year low of $10.80 and a one year high of $48.42. The stock has a 50-day simple moving average of $14.52 and a 200 day simple moving average of $17.22.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%.

Institutional Investors Weigh In On 10x Genomics

A number of hedge funds have recently made changes to their positions in TXG. Signaturefd LLC raised its holdings in shares of 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after buying an additional 1,452 shares during the last quarter. Capital Performance Advisors LLP bought a new stake in shares of 10x Genomics during the third quarter valued at approximately $35,000. Blue Trust Inc. raised its holdings in shares of 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after buying an additional 1,025 shares during the last quarter. Sound Income Strategies LLC raised its holdings in shares of 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after buying an additional 1,330 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of 10x Genomics during the fourth quarter valued at approximately $52,000. Institutional investors own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.